EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users

Elina Hietala iD, Anssi Solismaa, Markku Lähteenvuo, Ari V Ahola-Olli, Katja Häkkinen, Kimmo Suokas, Erkki Isometsä, Jaana Suvisaari, Tuula Kieseppä, Minna Holm, Jari Tiihonen, Jouko Lönnqvist und 6 weitere

Acta Neuropsychiatrica · 2025

DOI: 10.1017/neu.2025.11 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropsychiatrica, 2025. Verfasst von Elina Hietala und 17 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Medication Adherence, Aripiprazole, Risperidone. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone, and variations in CYP2D6 activity may affect treatment response or adverse effects. However, the impact of these variations on adherence and medication attitudes is unclear. This study investigates the relationships between CYP2D6 phenotype, self-reported adherence, adverse effects, and attitudes among aripiprazole and risperidone users. The study analysed data from the SUPER-Finland cohort of 10,474 adults with psychotic episodes, including 1,429 aripiprazole and 828 risperidone users. The Attitudes towards Neuroleptic Treatment (ANT) questionnaire assessed adherence and adverse effects in all patients, while medication-related attitudes were examined in a subgroup of 1,000 participants. Associations between CYP2D6 phenotypes and outcomes were analysed using logistic regression and beta regression in aripiprazole and risperidone groups separately. Among risperidone users, we observed no association between CYP2D6 phenotypes and adherence, adverse effects, or attitudes. Similarly, we found no link between adherence and CYP2D6 phenotypes among aripiprazole users. However, aripiprazole users with the ultrarapid CYP2D6 phenotype had more adverse effects (OR = 1.71, 95 % CI 1.03–2.90, p = 0.041). Among aripiprazole users, CYP2D6 ultrarapid phenotype was associated with less favourable attitudes towards antipsychotic treatment (β = −0.48, p = 0.023). These findings provide preliminary evidence that the ultrarapid CYP2D6 phenotype is associated with increased adverse effects and negative attitudes towards antipsychotic medication among aripiprazole users. CYP2D6 phenotype did not influence adherence, adverse effects, or attitudes among risperidone users.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6Medication AdherenceAripiprazoleRisperidoneAntipsychotic AgentsPsychotic DisordersAttitude to HealthPhenotypeSelf ReportLogistic ModelsFinlandHumansMaleFemaleAdultMiddle AgedCohort StudiesRegistries

Stichwörter der Autor:innen

Psychotic disordersantipsychotic agentscytochrome P-450 CYP2D6pharmacogeneticstreatment adherence and compliance

Substanzen

CYP2D6 protein, humanCytochrome P-450 CYP2D6AripiprazoleRisperidoneAntipsychotic Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Vanha Vaasa Hospital, Department of Forensic Psychiatry, Vaasa, Finland.
  • The Wellbeing Services County of Ostrobothnia, Department of Psychiatry, Seinäjoki, Finland.
  • Department of Psychiatry, Pirkanmaa Hospital District, Tampere, Finland.
  • Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

ORCID-Profile: Elina Hietala, Olli Kampman

Zitieren

APA

Hietala, E., Solismaa, A., Lähteenvuo, M., Ahola-Olli, A. V., Häkkinen, K., Suokas, K., Isometsä, E., Suvisaari, J., Kieseppä, T., Holm, M., Tiihonen, J., Lönnqvist, J., Hietala, J., Wegelius, A., Lahdensuo, K., Haaki, W., study SUPER-Finland, & Kampman, O. (2025). Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2025.11

Vancouver

Hietala E, Solismaa A, Lähteenvuo M, Ahola-Olli AV, Häkkinen K, Suokas K, et al. Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users. Acta Neuropsychiatrica. 2025. doi:10.1017/neu.2025.11

BibTeX
@article{Hietala2025,
  author = {Hietala, Elina and Solismaa, Anssi and Lähteenvuo, Markku and Ahola-Olli, Ari V and Häkkinen, Katja and Suokas, Kimmo and Isometsä, Erkki and Suvisaari, Jaana and Kieseppä, Tuula and Holm, Minna and Tiihonen, Jari and Lönnqvist, Jouko and Hietala, Jarmo and Wegelius, Asko and Lahdensuo, Kaisla and Haaki, Willehard and study SUPER-Finland, study SUPER-Finland and Kampman, Olli},
  title = {Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users},
  journal = {Acta Neuropsychiatrica},
  year = {2025},
  doi = {10.1017/neu.2025.11}
}
Kostenlos starten →